Search results for "Serotonin Uptake Inhibitor"

showing 8 items of 8 documents

Results from a prospective observational study of men with premature ejaculation treated with dapoxetine or alternative care: The PAUSE study

2014

Abstract Background Dapoxetine hydrochloride is a selective serotonin reuptake inhibitor and the first drug approved for the on-demand treatment of premature ejaculation (PE). Its safety was established in a thorough clinical development program. Objective To characterize the safety profile of dapoxetine in PE treatment and to report the incidence, severity, and type of adverse events. Design, setting, and participants We conducted a 12-wk, open-label, observational study with a 4-wk, postobservational contact. A total of 10 028 patients were enrolled, with 6712 patients (67.6%) treated with dapoxetine 30–60mg (group A)and 3316 (32.4%) treated with alternative care/nondapoxetine (group B). …

AdultComplementary TherapiesMalemedicine.medical_specialtyBenzylaminesAdolescentNauseaUrologyNaphthalenesDapoxetine Safety Cardiovascular events SyncopeSyncopeCardiovascular eventsYoung AdultInternal medicinePremature ejaculationmedicine80 and overCardiovascular events; Dapoxetine; Safety; Syncope; Adolescent; Adult; Aged; Aged 80 and over; Benzylamines; Complementary Therapies; Humans; Male; Middle Aged; Naphthalenes; Premature Ejaculation; Prospective Studies; Serotonin Uptake Inhibitors; Young AdultHumansProspective StudiesPremature EjaculationAdverse effectProspective cohort studyCardiovascular events; Safety; DapoxetineAgedCardiovascular events; Dapoxetine; Safety; Syncope; UrologyAged 80 and overSertralinebusiness.industrySettore MED/24 - UROLOGIAIncidence (epidemiology)Cardiovascular events; Dapoxetine; Safety; Syncope; Adolescent; Adult; Aged; Aged 80 and over; Benzylamines; Complementary Therapies; Humans; Male; Middle Aged; Naphthalenes; Premature Ejaculation; Prospective Studies; Serotonin Uptake Inhibitors; Young Adult; UrologyMiddle AgedDapoxetineCardiovascular events; Dapoxetine; syncope; SafetyDapoxetineAnesthesiaSerotonin Uptake InhibitorsObservational studymedicine.symptomSafetybusinessSelective Serotonin Reuptake Inhibitorsmedicine.drugCardiovascular events Dapoxetine Safety Syncope
researchProduct

Characterisation of serotonin transport mechanisms in rainbow trout peripheral blood lymphocytes: role in PHA-induced lymphoproliferation

1999

Abstract AbstractIn this study we investigated the serotonin transport mechanisms in rainbow trout (Oncorhynchus mykiss) peripheral blood lymphocytes We have observed that the transport of serotonin is a membrane transport process that have the properties of a secondary active transport system The binding isotherm of [3H]-paroxetine a serotonin transport blocker demonstrated a high-affinity binding site with a positive type of cooperativity Hill coefficient being higher than unity Known specific inhibitors of the mammalian serotonin transporter significantly inhibited the uptake process in fish lymphocytes In order to demonstrate the physiological relevance of the serotonin transporter in T…

AgonistSerotoninmedicine.medical_specialtySerotonin uptakemedicine.drug_classImmunologySerotonin transportNerve Tissue ProteinsLymphocyte ActivationInternal medicineCyclic AMPmedicineAnimalsLymphocytesPhytohemagglutininsSerotonin Uptake InhibitorsSerotonin transporterSerotonin Plasma Membrane Transport ProteinsMembrane GlycoproteinsbiologyMembrane Transport ProteinsBiological TransportMembrane transportEndocrinologyOncorhynchus mykissActive transportbiology.proteinSerotoninCarrier ProteinsSelective Serotonin Reuptake InhibitorsDevelopmental BiologyDevelopmental & Comparative Immunology
researchProduct

Pharmacokinetics of selective serotonin reuptake inhibitors

2000

The five selective serotonin reuptake inhibitors (SSRIs), fluoxetine, fluvoxamine, paroxetine, sertraline, and citalopram, have similar antidepressant efficacy and a similar side effect profile. They differ, however, in their pharmacokinetic properties. Under steady-state concentrations, their half-lives range between 1 and 4 days for fluoxetine (7 and 15 days for norfluoxetine) and between 21 (paroxetine) and 36 (citalopram) hr for the other SSRIs. Sertraline and citalopram show linear and fluoxetine, fluvoxamine, and paroxetine nonlinear pharmacokinetics. SSRIs underlie an extensive metabolism with high interindividual variability, whereby cytochrome P450 (CYP) isoenzymes play a major rol…

CYP2D6FluvoxamineCitalopramPharmacologyCitalopramSerotonergicbehavioral disciplines and activitiesFluoxetineSertralinemental disordersmedicineHumansDrug InteractionsPharmacology (medical)Serotonin Uptake InhibitorsPharmacologyClinical Trials as TopicFluoxetineSertralinebusiness.industryParoxetineParoxetineFluvoxaminebusinessSelective Serotonin Reuptake Inhibitorsmedicine.drugPharmacology & Therapeutics
researchProduct

Role of the amygdala in antidepressant effects on hippocampal cell proliferation and survival and on depression-like behavior in the rat

2021

The stimulation of adult hippocampal neurogenesis by antidepressants has been associated with multiple molecular pathways, but the potential influence exerted by other brain areas has received much less attention. The basolateral complex of the amygdala (BLA), a region involved in anxiety and a site of action of antidepressants, has been implicated in both basal and stress-induced changes in neural plasticity in the dentate gyrus. We investigated here whether the BLA modulates the effects of the SSRI antidepressant fluoxetine on hippocampal cell proliferation and survival in relation to a behavioral index of depression-like behavior (forced swim test). We used a lesion approach targeting th…

MaleLong-Term Potentiationlcsh:MedicineHippocampal formationElement-Binding ProteinAmygdala/*drug effects/physiopathologyHippocampusMemory FormationRats Sprague-Dawleyddc:616.890302 clinical medicineMedial Prefrontal CortexElevated Plus-MazeSerotonin Uptake Inhibitors/*pharmacologylcsh:ScienceBasolateral Amygdala0303 health sciencesMultidisciplinaryNeuroscience/Behavioral NeuroscienceDepressionNeurogenesisBLAAmygdalaImmunohistochemistryChronic FluoxetineAdult-RatNeuroscience/Psychologymedicine.anatomical_structureFluoxetine/*pharmacologyDepression/*pathologyAntidepressantAntidepressive Agents Second-GenerationSelective Serotonin Reuptake InhibitorsResearch ArticleEstrèsElevated plus mazemedicine.medical_specialtyAnimal-ModelAntidepressive Agents Second-Generation/*pharmacologyCell SurvivalAmygdala03 medical and health sciencesFluoxetineNeuroplasticityHippocampus/cytology/*drug effectsmedicineAnimalsPsychiatryMaze Learning030304 developmental biologyCell Proliferationbusiness.industryDentate gyrusMental Health/Mood Disorderslcsh:RBasolateral complex of the amygdaleRatsCell Proliferation/*drug effectsDentate Gyruslcsh:QCell Survival/*drug effectsbusinessNeuroscience030217 neurology & neurosurgeryBasolateral amygdala
researchProduct

Treatments used for obsessive-compulsive disorder-An international perspective.

2018

Objective The objective of this study was to characterise international trends in the use of psychotropic medication, psychological therapies, and novel therapies used to treat obsessive–compulsive disorder (OCD). Methods Researchers in the field of OCD were invited to contribute summary statistics on the characteristics of their samples. Consistency of summary statistics across countries was evaluated. Results The study surveyed 19 expert centres from 15 countries (Argentina, Australia, Brazil, China, Germany, Greece, India, Italy, Japan, Mexico, Portugal, South Africa, Spain, the United Kingdom, and the United States) providing a total sample of 7,340 participants. Fluoxetine (n = 972; 13…

MaleObsessive-Compulsive DisorderInternationalitymedicine.medical_treatmentDeep Brain StimulationSocial SciencesFluvoxamineBENZODIAZEPINASpharmacotherapyBenzodiazepines0302 clinical medicinePharmacology (medical)TERAPIA PSICOANALITICAPSICOFARMACOLOGIAantipsychotics; benzodiazepines; cross-cultural study; obsessive-compulsive disorder; pharmacotherapy; selective serotonin reuptake inhibitorsMiddle Aged3. Good healthExposure and response preventionantipsychotics; benzodiazepines; cross-cultural study; obsessive–compulsive disorder; pharmacotherapy; selective serotonin reuptake inhibitorsNeurologyPsychiatry and Mental HealthSerotonin Uptake Inhibitorscross-cultural studyAripiprazoleFemalebenzodiazepineSelective Serotonin Reuptake Inhibitorsmedicine.drugPsychosurgeryAntipsychotic AgentsAdultmedicine.medical_specialty:Ciências da Saúde [Ciências Médicas]Ciências Médicas::Ciências da SaúdeSerotonin reuptake inhibitor03 medical and health sciencesANTIPSICOTICOSobsessive–compulsive disorderselective serotonin reuptake inhibitorsmedicinePSICOTROPICOSHumansAntipsychoticPsychiatryFARMACOTERAPIAFluoxetineRisperidoneantipsychotics; benzodiazepines; cross-cultural study; obsessive–compulsive disorder; pharmacotherapy; selective serotonin reuptake inhibitors; Neurology; Neurology (clinical); Psychiatry and Mental Health; Pharmacology (medical)Science & Technologyselective serotonin reuptake inhibitorbusiness.industryTRASTORNO OBSESIVO COMPULSIVO030227 psychiatryantipsychoticPsychosurgeryantipsychoticsNeurology (clinical)business030217 neurology & neurosurgerySEROTONINAHuman psychopharmacology
researchProduct

Intracerebral Hemorrhage and Outcome After Thrombolysis in Stroke Patients Using Selective Serotonin-Reuptake Inhibitors.

2017

Background and Purpose— Selective serotonin-reuptake inhibitors (SSRIs) impair platelet function and have been linked to a higher risk of spontaneous intracerebral hemorrhage—an association that may be augmented by oral anticoagulants (OAC). We aimed to assess whether preadmission treatment with SSRIs in patients with acute ischemic stroke is associated with post-thrombolysis symptomatic intracerebral hemorrhage (sICH) and functional outcome. Methods— A multicenter retrospective analysis was conducted in prospective registries of patients treated by thrombolysis within 4.5 hours of stroke onset. The association between preadmission treatment with SSRIs and sICH (ECASS II definition [Europe…

Malemedicine.medical_specialtytherapeutic use [Anticoagulants]medicine.medical_treatmentSubgroup analysisepidemiology [Cerebral Hemorrhage]Risk AssessmentCohort Studies03 medical and health sciencesadverse effects [Serotonin Uptake Inhibitors]0302 clinical medicineModified Rankin ScaleInternal medicinemedicineHumansThrombolytic Therapy030212 general & internal medicineddc:610610 Medicine & healthStrokeCerebral HemorrhageAgedRetrospective StudiesAdvanced and Specialized NursingIntracerebral hemorrhageAged 80 and overtherapy [Cerebral Hemorrhage]business.industryAnticoagulantsThrombolysisOdds ratioMiddle Agedmedicine.diseaseadverse effects [Selective Serotonin Reuptake Inhibitors]Prognosisdrug therapy [Stroke]StrokeTreatment OutcomeAnesthesiaConcomitantSerotonin Uptake InhibitorsFemaleNeurology (clinical)Cardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgerySelective Serotonin Reuptake Inhibitorsepidemiology [Stroke]Cohort study
researchProduct

Italian Association of Sleep Medicine (AIMS) position statement and guideline on the treatment of menopausal sleep disorders

2019

Insomnia, vasomotor symptoms (VMS) and depression often co-occur after the menopause, with consequent health problems and reductions in quality of life. The aim of this position statement is to provide evidence-based advice on the management of postmenopausal sleep disorders derived from a systematic review of the literature. The latter yielded results on VMS, insomnia, circadian rhythm disorders, obstructive sleep apnea (OSA) and restless leg syndrome (RLS). Overall, the studies show that menopausal hormone therapy (MHT) improves VMS, insomnia, and mood. Several antidepressants can improve insomnia, either on their own or in association with MHT; these include selective serotonin reuptake …

Sleep Initiation and Maintenance Disordermedicine.medical_treatmentSerotonin and Noradrenaline Reuptake InhibitorPosition statementSleep medicine0302 clinical medicineSleep Initiation and Maintenance DisordersCognitive behavioraltherapy for insomnia (CBT-I)InsomniaSleep Wake Disorder030212 general & internal medicineContinuous positive airway pressureRestless legs syndromeSerotonin and Noradrenaline Reuptake InhibitorsCognitive behavioraltherapy for insomnia (CBT-I); Hormonereplacementtherapy (HRT); Menopause; Position statement; Sleepdisorders; Vasomotorsymptoms (VMS)Sleep Apnea Obstructive030219 obstetrics & reproductive medicineContinuous Positive Airway PressureDepressionObstetrics and GynecologySerotonin Uptake InhibitorAntidepressive AgentsMenopauseCognitive behavioral therapyCognitive behavioral therapy for insomnia (CBT-I)SleepdisordersAntidepressive AgentFemalemedicine.symptomMenopauseSelective Serotonin Reuptake Inhibitorsmedicine.drugHumanSleep Wake Disordersmedicine.medical_specialtyHormone Replacement TherapyVasomotor symptoms (VMS)MirtazapineCognitive behavioral therapy for insomnia (CBT-I); Hormone replacement therapy (HRT); Menopause; Position statement; Sleep disorders; Vasomotor symptoms (VMS); Antidepressive Agents; Cognitive Behavioral Therapy; Continuous Positive Airway Pressure; Depression; Exercise; Female; Humans; Mirtazapine; Quality of Life; Restless Legs Syndrome; Serotonin Uptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Sleep; Sleep Apnea Obstructive; Sleep Initiation and Maintenance Disorders; Sleep Wake Disorders; Hormone Replacement Therapy; MenopauseMirtazapineSettore MED/10 - Malattie Dell'Apparato RespiratorioHormone replacement therapy (HRT)Hormonereplacementtherapy (HRT)General Biochemistry Genetics and Molecular Biology03 medical and health sciencesRestless Legs Syndromemental disordersmedicineHumansExerciseSleep disorderCognitive Behavioral Therapybusiness.industryVasomotorsymptoms (VMS)medicine.diseasenervous system diseasesObstructive sleep apneaMenopause sleep disorders vasomotor symptoms (VMS) hormone replacement therapy (HRT) Cognitive Behavioral Therapy for Insomnia (CBT-I) Position StatementPhysical therapyQuality of LifebusinessSleep
researchProduct

Group 1 ITI Consensus Report: The influence of implant length and design and medications on clinical and patient-reported outcomes

2018

The following article: Jung, R.E., Al-Nawas, B., Araujo, M., Avila-Ortiz, G., Barter, S., Brodala, N., ... Windisch, P. (2018). Group 1 ITI Consensus Report: The influence of implant length and design and medications on clinical and patient-reported outcomes. Clinical Oral Implants Research, 29(S16), 69-77, can be accessed at https://doi.org/10.1111/clr.13342. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. Objectives: The aim of Working Group 1 was to address the influence of different local (implant length, diameter, and design) and systemic (medications) factors on clinical, radiographic, and patient‐re…

medicine.medical_treatmentOsteoporosisbiological complicationsDentistryOsteoporosis/complicationsmeta-analysilaw.inventionProton Pump Inhibitors/adverse effects0302 clinical medicineRandomized controlled triallawRadiography DentalDental Restoration FailureDental implanthumans610 Medicine & healthclinical decision-makingdental implantDiphosphonatesnarrow diameter3504 Oral SurgeryJaw Edentulous Partially05 social sciencesDental Implantation EndosseousImplant failuredrugsmall dental implantVDP::Medisinske Fag: 700::Klinisk odontologiske fag: 830failureclinical decision‐makingDiphosphonates/adverse effectsMeta-analysisrandomized controlled trials/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingepidemiologymedicationOral SurgerySelective Serotonin Reuptake InhibitorsConsensusreview610 Medicine & healthsurvival03 medical and health sciences10068 Clinic of Reconstructive DentistrySDG 3 - Good Health and Well-beingdental implants0502 economics and businessmedicineshort dental implantsHumansbiological complicationPatient Reported Outcome MeasureshumanSurvival ratesmall dental implantsDental Implantsbusiness.industryJaw Edentulous Partially/rehabilitationshort dental implantProton Pump Inhibitors030206 dentistrymedicine.diseaseendosseous implantSurvival AnalysisVDP::Medical disciplines: 700::Clinical dentistry disciplines: 830Dental Prosthesis Designmeta‐analysisRelative riskrandomized controlled trialOsteoporosis050211 marketingImplantSerotonin Uptake Inhibitors/adverse effectsbusinessosteotomySystematic Reviews as Topic
researchProduct